Key result
Micra Transcatheter Pacing System was successfully implanted in 98.5% of patients, with stable electrical measurements and one major adverse event over a mean follow-up of 10.4 months.
Why the study?
Does Micra TPS implantation provide safe and effective pacing in patients with Class I or II indications for ventricular pacing, including challenging cases?
Population
66 patients with a Class I or II indication for ventricular pacing.
Design
Cohort
Follow-up
10.4 ± 6.1 months
Authors
Loading...
Supports real-world feasibility of Micra; extends early trials but leaves long-term safety open.
Cohort (n=66)
No
Does Micra TPS implantation provide safe and effective pacing in patients with Class I or II indications for ventricular pacing, including challenging cases?
Leadless pacing with the Micra TPS demonstrates high implant success and stable electrical performance in a real-world cohort, including patients with challenging conditions for conventional pacing.
Garweg et al. (2017) conducted a cohort in Class I or II indication for ventricular pacing (n=66). Micra Transcatheter Pacing System (TPS) was evaluated on successful implantation. Micra Transcatheter Pacing System was successfully implanted in 98.5% of patients, with stable electrical measurements and one major adverse event over a mean follow-up of 10.4 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: